Risorse esterne
Opinione della community
Prezzo Variazione Volume
1.3 -3.7 €
P/E Obiettivo ad 1anno
0 3 €

Compra - Vendi

Tutte le tue transazioni per questo titolo

Devi effettuare l'accesso


Altri utenti che hanno investito

Transations in last week
Buy: 28
Sell : 9

maggieramon Ramiro august94 cfalco ghed Simone Bonzanini P18634 Zullo Carmine Niko91 LucaMazzu91



The Unified Clarity of The Technical Chart For Merrimack Pharmaceuticals, Inc. (MACK) Is Amazing - NY Stock News

Merrimack Pharmaceuticals, Inc. (MACK) has created a compelling message for traders in the most recent trading. That message has grown stronger as the technical chart setup has developed into a more composite picture for the stock. This is the ...altro » Leggi

​SEC charges two former Ariad executives with insider trading - Boston Business Journal

One recent case was filed against Songjiang Wang, a former employee at Merrimack Pharmaceuticals, who is accused of passing tips about the Cambridge firm to an employee of another local biotech, Akebia Therapeutics. Both defendants have pled not ...altro » Leggi

Merrimack Pharmaceuticals, Inc. (MACK) noted a price change of -3.70% and Xtant Medical Holdings, Inc. (XTNT ... - Stocks Gallery

In recent trading day Merrimack Pharmaceuticals, Inc. (MACK) stock showed the move of -3.70% with the closing price of $1.30. Closing price generally refers to the last price at which a stock trades during a regular trading session. The company moved ...altro » Leggi

Target Price for Merrimack Pharmaceuticals, Inc. (MACK) now above close for Thursday - NY Stock News

Merrimack Pharmaceuticals, Inc. (MACK) has presented a rich pool of technical data in recent sessions. These are the trends we've ... Recent trading for (MACK) has highlighted key trends upon which sound decisions can be based. The levels established ...altro » Leggi

14 hedge funds buy Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) for the first time - Post Analyst

Merrimack Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Head of Research Drummond Daryl C has sold 4,097 shares of Merrimack Pharmaceuticals, Inc. (MACK) in trading session dated ... Leggi

Merrimack Pharmaceuticals, Inc. (MACK) traded with volume of 5.36 Million shares in last trading session - StandardOracle

Merrimack Pharmaceuticals, Inc. (MACK) added 11.45% to reach $1.46 in the previous trading session. Overall, 5.36 Million shares exchanged hands versus its average trading volume of 3.71 Million shares. The relative volume of the stock is 1.44, while ... Leggi

Merrimack Pharmaceuticals, Inc. (MACK) went down -1.69% in the last trading session - HugoPress

While looking at the SMA values of Merrimack Pharmaceuticals, Inc. (MACK), the 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend. The 200 SMA is considered so ... Leggi

Merrimack Pharmaceuticals, Inc. (MACK) Delivers Clear Picture With Technicals - NY Stock News

Merrimack Pharmaceuticals, Inc. (MACK) is now trading with a very clear set of technicals. Taken together they paint a very compelling picture of how investors and traders should be approaching MACK. Technical charts are very important tools for ... Leggi

Merrimack Pharmaceuticals, Inc. (MACK) closes -56.33% below ... - NY Stock News

Merrimack Pharmaceuticals, Inc. (MACK) is looking very interesting as a trading opportunity right now. The technical setup offers the best window into what ...altro » Leggi

Review of Price Trends: Portola Pharmaceuticals, Inc. (PTLA) and Merrimack Pharmaceuticals, Inc. (MACK) trades ... - NYSE Journal (press release)

Shares of Portola Pharmaceuticals, Inc. (PTLA) made a gain as they have increased 1.52% to end at $56.91 on Monday. Shares seen boost move of 55.92% in the past five days; the stock price is now 153.61% so far on the year — still in positive territory.altro » Leggi